Original article A phase II study of 9-aminocamptothecin in advanced non-small-cell lung cancer

Median time to progression was 2.3 months and the median survival for the entire study population 5.4 months with a one-year survival rate of 30%. The one-year survival rate for 27 patients who received second line chemotherapy was 56.7%. Toxicities at 1416 ug/m 2 /d included grade 4 neutropenia and thrombocytopenia in six and five of 13 patients, respectively; at 1100 ug/m 2 /d these toxicities were observed in 12 and three of 45 patients, respectively. Conclusion: 9-AC has modest single-agent activity in previously untreated NSCLC. Its further evaluation at the dose and schedule employed in this study does not seem indicated. Exploration of more prolonged administration schedules may be warranted.

[1]  L. Saltz,et al.  The camptothecins , 2003, The Lancet.

[2]  N. Kemeny,et al.  9‐aminocamptothecin by 72‐hour continuous intravenous infusion is Inactive in the treatment of patients with 5‐fluorouracil‐refractory colorectal carcinoma , 1997, Cancer.

[3]  S. Arbuck,et al.  Phase II trial of 9-aminocamptothecin administered as a 72-hour continuous infusion in metastatic colorectal carcinoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Rothenberg.  Topoisomerase I inhibitors: review and update. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  L. Grochow,et al.  Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  S. Arbuck,et al.  Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  R. A. Robinson,et al.  Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  S. Arbuck,et al.  Camptothecin and its analogs. An overview of their potential in cancer therapeutics. , 1996, Annals of the New York Academy of Sciences.

[9]  D. Toppmeyer,et al.  A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  S. Culine,et al.  Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. , 1994, Cancer research.

[11]  H. Hochster,et al.  Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  P Chomy,et al.  Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  L. Kalish,et al.  Phase II study of topotecan in metastatic non-small-cell lung cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  M. Fukuoka,et al.  Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  G. Weiss,et al.  Phase I and pharmacokinetic trial of weekly CPT-11. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  P. Pantazis,et al.  Efficacy of camptothecin congeners in the treatment of human breast carcinoma xenografts. , 1993, Oncology research.

[17]  P. Pantazis,et al.  Complete inhibition of growth followed by death of human malignant melanoma cells in vitro and regression of human melanoma xenografts in immunodeficient mice induced by camptothecins. , 1992, Cancer research.

[18]  L. Liu,et al.  DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts. , 1989, Science.